World Health Organization, Media centre. Cancer Fact sheet, February 2017; http://www.who.int/mediacentre/factsheets/fs297/en/

Hanahan D and Weinberg R.A. Hallmarks of Cancer. Cell. 2011; 144(5): 646-674.

World Health Organization, Chan M. Prevention is best option to tackle noncommunicable diseases in the Opening remarks at the Global noncommunicable disease network (NCDnet) global forum, February 2010; http://www.who.int/dg/speeches/2010/ncdnet_forum_20100224/en/

Sethi S, Ali S. Philip P.A. and Sarkar F.H. Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy. Int J Mol Sci. 2013; 14(7):14771-14784.

Ku C. S., Cooper D. N. and Roukos D. H. Clinical Relevance of Cancer Genome Sequencing. World J Gastroenterol. 2013; 19(13): 2011–2018.

Ogino S., King E. E., Beck A. H., Sherman M. E., Milner, D. A. and Giovannucci E. Interdisciplinary Education to Integrate Pathology and Epidemiology: Towards Molecular and Population-level Health Science. Am J Epidemiol. 2012; 176(8): 659–667.

Staehler C. F., Keller A., Leidinger P., Backes C., Chandran A., Wischhusen J., Meder B. and Meese E. Whole miRNome-wide Differential Co-expression of microRNAs. Genomics Proteomics Bioinforma. 2012; 10: 285–294.

Swerdlow S. H. and Campo E. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed; International Agency for Research on Cancer Press: Lyon, France, 2008.

FDA U.S. Food & Drug Administration. Recently-Approved Devices PD-L1 IHC 28-8 pharmDx-P150025, November 2015; https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm473390.htm

Scheerens H., Malong A., Bassett K., Boyd Z., Gupta V., Harris J., Mesick C., Simnett S., Stevens H., Gilbert H., Risser P., Kalamegham R., Jordan J., Engel J., Chen S., Essioux L. and Williams J. A. Current Status of Companion and Complementary Diagnostics: Strategic Consideration for Development and Launch. Clin Transl Sci. 2017; 10(2): 84-92.

FDA Clears Thermo Fisher NGS Companion Diagnostic for Three NSCLC Treatments in GEN News Highlights, 23 June 2017; http://www.genengnews.com/gen-news-highlights/fda-clears-thermo-fisher-ngs-companion-diagnostic-for-three-nsclc-treatments/81254559.

Minari R., Bordi P. and Tiseo M. Third-generation E Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in T790M-positivenon-small Cell Lung Cancer: Review on Emerged Mechanisms of Resistance. Transl Lung Cancer Res. 2016; 5:695–708.